Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 ANKRD26 mRNA levels and methylation percentage of the CpG sites, − 689, − 659, and − 651, in MHO (n = 5) and MUO (n = 15) individuals. Obese subjects have been classified as MHO or MUO based on Wildman et al. [32]. In particular, metabolically unhealthy obese subjects are defined by the presence of two or more of these 6 criteria: blood pressure systolic ≥ 130 mmHg and/or diastolic ≥ 85 mmHg or use of anti-hypertensive drugs; fasting triglycerides ≥ 150 mg dl−1 or use of lipid-lowering drugs; fasting HDL-C ≤ 40 mg dL−1 in men and ≤ 50 mg dL−1 in women or use of lipid-lowering drugs; fasting glucose ≥ 100 mg dl−1 or use of anti-diabetic drugs; HOMA-IR > 90th percentile; and CRP > 90th percentile, while metabolically healthy obese subjects are defined by the presence of 0 or 1 of the previous criteria. For symmetrically distributed variables, data are shown as mean ± SD and the statistical difference between the two groups was tested by two-tailed unpaired Student’s t test. For skewed distributions, data are shown as median (first quartile—Q1; third quartile—Q3) and statistical differences between the two groups were tested using Mann-Whitney U test. HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; SBP, systolic blood pressure; DBP, diastolic blood pressure; CRP, C-reactive protein; HOMA-IR, homeostatic model assessment of insulin resistance

From: Epigenetic silencing of the ANKRD26 gene correlates to the pro-inflammatory profile and increased cardio-metabolic risk factors in human obesity

 MHOMUOp value
Wildman criteria
 Glucose, mg dL−182.8 ± 8.399.6 ± 42.3n.s.
 HDL-C, mg dL−153.8 ± 13.644.4 ± 8.0n.s.
 SBP, mmHg119.0 ± 10.2135.3 ± 10.40.007
 DBP, mmHg84.0 ± 4.285.0 ± 6.0n.s.
 TG, mg dL−170.0 (62.2; 119.5)137.0 (104.0; 170.0)0.036
 CRP, mg L−12.0 (0.5; 19.7)9.1 (4.4; 17.2)n.s.
 HOMA-IR1.6 (1.4; 2.2)4.3 (3.0; 5.7)0.006
ANKRD26 mRNA, AU × 10−55.7 (4.4–7.0)2.2 (1.6–3.8)0.004
CpG − 689, % CpG methylation36.7 ± 4.757.8 ± 15.70.009
CpG − 569, % CpG methylation46.0 ± 8.951.2 ± 19.3n.s.
CpG − 651, % CpG methylation54.0 ± 16.762.6 ± 17.7n.s.